Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
The Respiratory Syncytial Virus (RSV) vaccine will be rolled out to some older islanders as well as pregnant women. | ITV ...
NHS bosses have urged Britons to get vaccinated this autumn to prevent a “tripledemic” of flu, covid-19 and respiratory ...